Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EBITDA (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of EBITDA data on record, last reported at -$114.0 million in Q4 2025.

  • For Q4 2025, EBITDA changed N/A year-over-year to -$114.0 million; the TTM value through Dec 2025 reached -$341.0 million, changed N/A, while the annual FY2025 figure was -$386.0 million, 16.97% down from the prior year.
  • EBITDA reached -$114.0 million in Q4 2025 per RCUS's latest filing, up from -$122.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $278.2 million in Q4 2021 and bottomed at -$122.0 million in Q1 2025.
  • Average EBITDA over 5 years is -$60.8 million, with a median of -$78.0 million recorded in 2021.
  • The widest YoY moves for EBITDA: up 636.13% in 2021, down 4535.53% in 2021.
  • A 5-year view of EBITDA shows it stood at $278.2 million in 2021, then crashed by 126.76% to -$74.4 million in 2022, then fell by 22.24% to -$91.0 million in 2023, then fell by 15.38% to -$105.0 million in 2024, then decreased by 8.57% to -$114.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$114.0 million in Q4 2025, -$122.0 million in Q1 2025, and -$105.0 million in Q3 2024.